Resultados globales: 4 registros encontrados en 0.03 segundos.
Artículos, Encontrados 4 registros
Artículos Encontrados 4 registros  
1.
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT) : an international, randomised, phase 3, non-inferiority trial / Iveson, Timothy J (Southampton University Hospital NHS Foundation Trust, Southampton, UK) ; Kerr, Rachel S (Department of Oncology, University of Oxford, Oxford, UK) ; Saunders, Mark P (The Christie Hospital, Manchester, UK) ; Cassidy, Jim (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ; Hollander, Niels Henrik (Department of Oncology and Palliative Care, Zealand University Hospital, Naestved, Denmark) ; Tabernero, Josep (VHIO) ; Haydon, Andrew (Australasian Gastro-Intestinal Trials Group, Melbourne, VIC, Australia) ; Glimelius, Bengt (IGP, University of Uppsala, Uppsala, Sweden) ; Harkin, Andrea (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ; Allan, Karen (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ; McQueen, John (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ; Scudder, Claire (OCTO, University of Oxford, Department of Oncology, Oxford, UK) ; Boyd, Kathleen Anne (Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK) ; Briggs, Andrew (Center for Health and Policy Outcomes, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Centre, New York, NY, USA) ; Waterston, Ashita (Beatson West of Scotland Cancer Centre, Glasgow UK) ; Medley, Louise (Royal United Hospital, Bath, UK) ; Wilson, Charles (Addenbrookes Hospital (Cambridge, Regne Unit)) ; Ellis, Richard (Royal Cornwall Hospital NHS Trust, Truro, UK) ; Essapen, Sharadah (St Luke's Cancer Centre, Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK) ; Dhadda, Amandeep S (Castle Hill Hospital, Hull, UK) ; Harrison, Mark (Mount Vernon Cancer Centre, Northwood, UK) ; Falk, Stephen (Bristol Cancer Institute, Bristol, UK) ; Raouf, Sherif (Barking Havering and Redbridge University Hospital NHS Trust, Barking, UK) ; Rees, Charlotte (Southampton University Hospital NHS Foundation Trust, Southampton, UK) ; Olesen, Rene K (Department of Oncology, Aarhus University Hospital, Aarhus, Denmark) ; Propper, David (Barts Cancer Institute, Queen Mary University of London, London, UK) ; Bridgewater, John (UCL Cancer Institute, University College London, London UK) ; Azzabi, Ashraf (Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK) ; Farrugia, David (Gloucestershire Oncology Centre, Cheltenham General Hospital, Cheltenham, UK) ; Webb, Andrew (Brighton and Sussex University Hospital Trust, Brighton, UK) ; Cunningham, David (Royal Marsden Hospital, London, UK) ; Hickish, Tamas (Poole Hospital, Bournemouth University, Bournemouth, UK) ; Weaver, Andrew (Department of Oncology, Oxford University Hospitals Foundation Trust, Oxford, UK) ; Gollins, Simon (North Wales Cancer Treatment Centre, Rhyl, UK) ; Wasan, Harpreet S (Hammersmith Hospital, Imperial College London, London, UK) ; Paul, James (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ; Universitat Autònoma de Barcelona
6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of treatment. [...]
2018 - 10.1016/S1470-2045(18)30093-7
The Lancet. Oncology, Vol. 19 (april 2018) , p. 562-578  
2.
18 p, 641.8 KB Return to the sea, get huge, beat cancer : An analysis of Cetacean genomes including an assembly for the humpback whale (Megaptera novaeangliae) / Tollis, Marc (Northern Arizona University. School of Informatics, Computing and Cyber Systems) ; Robins, Jooke (Center for Coastal Studies (USA)) ; Webb, Andrew E. (Temple University. Center for Computational Genetics and Genomics) ; Kuderna, Lukas F.K. (Universitat Pompeu Fabra. Institut de Biologia Evolutiva) ; Caulin, Aleah F. (University of Pennsylvania. Genomics and Computational Biology Program) ; Garcia, Jacinda D. (Arizona State University. School of Life Sciences) ; Bèrubè, Martine (University of Groningen. Groningen Institute of Evolutionary Life Sciences) ; Pourmand, Nader (University of California Santa Cruz. Jack Baskin School of Engineering) ; Marques-Bonet, Tomas (Institut Català de Paleontologia Miquel Crusafont) ; O'Connell, Mary J. (University of Nottingham. Computational and Molecular Evolutionary Biology Research Group) ; Palsbøll, Per J. (University of Groningen. Groningen Institute of Evolutionary Life Sciences) ; Maley, Carlo C. (Arizona State University. School of Life Sciences)
Cetaceans are a clade of highly specialized aquatic mammals that include the largest animals that have ever lived. The largest whales can have ∼1,000× more cells than a human, with long lifespans, leaving them theoretically susceptible to cancer. [...]
2019 - 10.1093/molbev/msz099
Molecular biology and evolution, Vol. 36, Issue 8 (August 2019) , p. 1746-1763  
3.
13 p, 561.5 KB Gene fusions derived by transcriptional readthrough are driven by segmental duplication in human / McCartney, Ann M. (Dublin City University. Bioinformatics and Molecular Evolution Group) ; Hyland, Edel M. (Queens University Belfast. Institute for Global Food Security) ; Cormican, Paul (Animal & Grassland Research and Innovation Centre. Teagasc Animal and Bioscience Research Department (Ireland)) ; Moran, Raymond J. (Dublin City University. Bioinformatics and Molecular Evolution Group) ; Webb, Andrew E. (Dublin City University. Bioinformatics and Molecular Evolution Group) ; Lee, Kate D. (Massey University (New Zealand)) ; Hernandez Rodriguez, Jessica (Universitat Pompeu Fabra. Institut de Biologia Evolutiva) ; Prado Martinez, Javier (Universitat Pompeu Fabra. Institut de Biologia Evolutiva) ; Creevey, Christopher J. (Aberystwyth University. Institute of Biological, Environmental and Rural Sciences) ; Aspden, Julie L. (University of Leeds. School of Molecular and Cellular Biology) ; McInerney, James O. (University of Nottingham. School of Life Sciences) ; Marques-Bonet, Tomas (Institut Català de Paleontologia Miquel Crusafont) ; O'Connell, Mary J. (University of Nottingham. School of Life Sciences)
Gene fusion occurs when two or more individual genes with independent open reading frames becoming juxtaposed under the same open reading frame creating a new fused gene. A small number of gene fusions described in detail have been associated with novel functions, for example, the hominid-specific PIPSL gene, TNFSF12, and the TWE-PRIL gene family. [...]
2019 - 10.1093/gbe/evz163
Genome biology and evolution, Vol. 11, Issue 9 (September 2019) , p. 2678-2690  
4.
7 p, 434.6 KB SCOT : a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer / Robles-Zurita, José (University of Glasgow. Institute of Health and Wellbeing) ; Boyd, Kathleen A. (University of Glasgow. Institute of Health and Wellbeing) ; Briggs, Andrew H. (University of Glasgow. Institute of Health and Wellbeing) ; Iveson, Timothy (Southampton University Hospital NHS Foundation Trust) ; Kerr, Rachel S. (University of Oxford. Department of Oncology) ; Saunders, Mark P. (The Christie Hospital) ; Cassidy, Jim (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ; Hollander, Niels Henrik (Zealand University Hospital, Department of Oncology and Palliative Care, Rǻdmandsengen 5) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Segelov, Eva (Australasian Gastro-Intestinal Trials Group (AGITG) and Monash University and Monash Health) ; Glimelius, Bengt (University of Uppsala) ; Harkin, Andrea (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ; Allan, Karen (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ; McQueen, John (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ; Pearson, Sarah (University of Oxford. Department of Oncology, OCTO) ; Waterston, Ashita (Beatson West of Scotland Cancer Centre) ; Medley, Louise (Royal United Hospital) ; Wilson, Charles (Addenbrookes Hospital (Cambridge, Regne Unit)) ; Ellis, Richard (Royal Cornwall Hospitals NHS Trust) ; Essapen, Sharadah (St Luke's Cancer Centre, Royal Surrey County Hospital NHS Foundation Trust) ; Dhadda, Amandeep S. (Castle Hill Hospital) ; Hughes, Rob (Mount Vernon Cancer Centre) ; Falk, Stephen (Bristol Cancer Institute, Bristol, UK) ; Raouf, Sherif (Barking Havering and Redbridge University Hospital NHS Trust, Barking, UK) ; Rees, Charlotte (Southampton University Hospital NHS Foundation Trust) ; Olesen, Rene K (Zealand University Hospital, Department of Oncology and Palliative Care, Rǻdmandsengen 5) ; Propper, David (Queen Mary, University of London. Barts Cancer Institute) ; Bridgewater, John (University College London) ; Azzabi, Ashraf (Newcastle upon Tyne Hospitals NHS Foundation Trust) ; Farrugia, David (Gloucestershire Oncology Centre, Cheltenham General Hospital) ; Webb, Andrew (Brighton and Sussex University Hospital Trust) ; Cunningham, David (Royal Marsden (funded by NIHR BRC at the Royal Marsden)) ; Hickish, Tamas (Poole Hospital/Bournemouth University) ; Weaver, Andrew (Churchill Hospital, Oxford University Hospitals Foundation Trust) ; Gollins, Simon (North Wales Cancer Treatment Centre, Rhyl, UK) ; Wasan, Harpreet S (Hammersmith Hospital, Imperial College London) ; Paul, James (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences)
The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus the usually given 6 months (6 M) of adjuvant chemotherapy in colorectal cancer. [...]
2018 - 10.1038/s41416-018-0319-z
British Journal of Cancer, Vol. 119 (november 2018) , p. 1332-1338  

Vea también: autores con nombres similares
2 Webb, A. F.
61 Webb, A.F.
2 Webb, Andrew E
2 Webb, Andrew E.
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.